In- vitro and in-vivo screening of Hypoglycemics.

49
In-vivo and In-vitro Screening of Hypoglycemics 21/06/2022 1 Presented by Kamlesh V. Warokar M.Pharm (Semister-I) (Dept. of Pharmacology) S.I.O.P., Pune.

Transcript of In- vitro and in-vivo screening of Hypoglycemics.

Page 1: In- vitro and in-vivo screening of Hypoglycemics.

02/05/2023

In-vivo and In-vitro Screening of Hypoglycemics

1

Presented by Kamlesh V. Warokar

M.Pharm (Semister-I) (Dept. of Pharmacology)

S.I.O.P., Pune.

Page 2: In- vitro and in-vivo screening of Hypoglycemics.

02/05/2023

• Introduction & Type Of D.M.

• Symptoms of D.M.

• Classification of Hypoglycemic drugs.

• In-vivo screening of Hypoglycemics.

• In-vitro screening of Hypoglycemics.

• Evaluation Parameter.

• References.

2

Contents

Page 3: In- vitro and in-vivo screening of Hypoglycemics.

02/05/2023

INTRODUCTION

• Diabetes Mellitus(DM) is a metabolic disorder characterized by hyperglycemia, glycosuria, hyperlipidaemia, & ketonaemia.

• Hyperglycemia is a metabolic disorder characterized by high blood sugar level which may leads to diabetes mellitus.

• High blood glucose happen when the body has too little insulin or when body can not use insulin properly.

• On this basis diabetes mellitus classified as : Type I- Insulin Dependent Diabetes Mellitus(IDDM), Type II-Noninsulin Dependent Diabetes Mellitus

(NIDDM). 3

(K.D.Tripathi et al.)

Page 4: In- vitro and in-vivo screening of Hypoglycemics.

02/05/20234

1. Juvenile onset of DM. 2. Beta cells destruction in

pancreatic islets. 3. Less common. 4. Have low degree of genetic

predisposition.

1. Maturity onset of DM. 2. Low insulin circulation &

moderate reduction in beta cell mass.

3. Most common. 4. High degree of genetic

predisposition.

TYPE 1 TYPE 2

(K.D.Tripathi et al.)

Page 5: In- vitro and in-vivo screening of Hypoglycemics.

02/05/20235

SYMPTOMS OF HYPERGLYCEMIA

Page 6: In- vitro and in-vivo screening of Hypoglycemics.

02/05/20236

Major Symptoms

Page 7: In- vitro and in-vivo screening of Hypoglycemics.

02/05/2023

1. SULFONYLUREAS A. First generation- Tolbutamide, Chloropropamide.

B. Second generation- Glipizide, Gliclazide. 2. BIGUANIDES- Metformin.

3. MEGLITINIDE- Repaglinide, Nateglinide

4. THIAZOLIDINEDOINES- Pioglitazone.

7

CLASSIFICATION OF HYPOGLYCEMIC DRUGS

(K.D.Tripathi, et al.)

Page 8: In- vitro and in-vivo screening of Hypoglycemics.

02/05/2023

1. Streptozotocin induced diabetes2. Alloxan induced diabetes3. Pancreatectomy in dogs4. Other diabetogenic compounds5. Hormone induced diabetes6. Insulin deficiency due to insulin

antibodies7. Virus induced diabetes

8

METHODS FOR SCREENING OF HYPOGLYCEMICS

1. In vivo models for IDDM

(Vogel,G.H.,et al.)

Page 9: In- vitro and in-vivo screening of Hypoglycemics.

02/05/2023

A. Spontaneous or genetically derived diabetic animal.

B. Diet / Nutrition induced diabetic animal.

C. Neonatal STZ induced diabetic animal.

D. Transgenic diabetic animal.

9

2. In vivo models for NIDDM

(K. Srinivasan & P. Ramarao)

Page 10: In- vitro and in-vivo screening of Hypoglycemics.

02/05/2023

INVITRO SCREENING OF HYPOGLYCEMICS

1. Effect on Liver

2. Effect on Muscles

3. Effect on Pancreas

4. Effect on Adipose Tissue

10

(Vogel,G.H.,et al.)

Page 11: In- vitro and in-vivo screening of Hypoglycemics.

02/05/202311

ANIMALS USED

Page 12: In- vitro and in-vivo screening of Hypoglycemics.

02/05/202312

1. STREPTOZOTOCIN INDUCED DIABETES

Male Wister Rats(150-220gm) are injected i.p. with 60mg/kg STZ prepared in citrated buffer.

Three phases of changed blood glucose level are observed.

Principle and Rationale

Procedure

IN VIVO MODELS FOR IDDM

Rakieten et al.(1963) discovered diabetogenic activity of the antibiotic Streptozotocin. Basic principle is compound is found to be cytotoxic to beta-cells of the pancreas.  

Page 13: In- vitro and in-vivo screening of Hypoglycemics.

02/05/2023

Initially after 3 hrs glucose level increased up to 150-200mg/dl . After 8 hrs, serum insuline values are incresed

up to 4 times. Hypoglycemic phase followed by hyperglycemia.

After 24-48 hours hyperglycemia already occur reaching values 800mg/dl with glycosuria & ketonemia.

Histologically beta cells are degranulated.

13

After 14 days animal used for pharmacological test.

(Vogel,G.H.et al.)

Page 14: In- vitro and in-vivo screening of Hypoglycemics.

02/05/202314

2. ALLOXAN INDUCED DIABETES

Purpose and Rationale

Frerichs(1968) & Creutzfeldt(1971)- Chemically induced diabetes in animals.

Procedure Animal is injected with a single dose [100 mg/kg body weight] dissolved in normal saline by i.p. route

Animals are kept for 48 hours during which food and water is allowed.

Page 15: In- vitro and in-vivo screening of Hypoglycemics.

02/05/202315

Blood glucose levels show triphasic response with hyperglycemia for 1 hour followed by hypoglycemia that lasts

for 6 hours & stable hyperglycemia after 48 hours.

Animals showing fasting blood glucose level above 140 mg/dl after 48 hour are considered diabetic

For a period of six weeks, drug samples to be screened are administered orally

Page 16: In- vitro and in-vivo screening of Hypoglycemics.

02/05/202316

After six weeks of treatment, blood samples are collected from 8 hour fasting animals (can be collected via orbita sinus through a pipette)

The serum glucose level is estimated by glucose oxidase-peroxidase method [GOD-POD] using autoanalyser.

(Vogel,G.H.,et al.)

Page 17: In- vitro and in-vivo screening of Hypoglycemics.

02/05/202317

Animal used

Beagle dogs 60 mg/kg(i.v)

Wistar rat 100-175 mg/kg(s.c)

Rabbits 150mg/kg (via ear vein)

Page 18: In- vitro and in-vivo screening of Hypoglycemics.

02/05/202318

Mechanism Of Action

(S. Lenzen.)

Page 19: In- vitro and in-vivo screening of Hypoglycemics.

02/05/202319

3. PANCREATECTOMY IN DOGS

Principle or Rationale

Procedure

Dogs-(12-16kg)

Anesthesia- Phenobarbital sodium (50mg/kg).Remove fur and disinfect.

Incision- Xyphoid to Umbilicus.

Self retaining retractor applied. Pancreas is brought in operating field. Pancreas separated from duodenum and

dissected freely.

Diabetes can be achieved by removal of pancreas.Bomskov(1910)- severe diabetic symptoms in dogs.

Von Mehring & Minkowski(1890)- polyuria, polydipsia, after removal of pancreas.

(Vogel,G.H.,et al.)

Page 20: In- vitro and in-vivo screening of Hypoglycemics.

02/05/202320

PANCREATECTOMY

Page 21: In- vitro and in-vivo screening of Hypoglycemics.

02/05/2023

RETRACTOR

21

Page 22: In- vitro and in-vivo screening of Hypoglycemics.

02/05/202322

• distal pancreatectomy surgery medicine surgical procedures.mp4

Page 23: In- vitro and in-vivo screening of Hypoglycemics.

02/05/202323

4. OTHER DIABETOGENIC AGENTS

Purpose and Rationale

Procedure Chleators such as dithizone injected in rabbit at dose of 40-100mg/kg which leads to triphasic glycemic reaction.

Phase 1- Increased blood glucose level after 2hr.Phase 2- Hypoglycemic phase after 8hr.

Phase 3 – Permanent hyperglycemia after24-72hr.

Diabetogenic agents are Dithizone, Goldthioglucose or monosodiun glutamate. Rabbit, Cats, Hamster rat and mice can be employed for this model.

(Vogel,G.H.,et al.)

Page 24: In- vitro and in-vivo screening of Hypoglycemics.

02/05/202324

5. HORMONE INDUCED DIABETESGrowth

hormone

Cotes et al., (1949) Animals used are generally adult Cats and Dogs.

Repeated administration of GH induce diabetes with the symptoms of ketonuria & ketonemia.

Rats does not shows diabetes but grow faster and shows striking hypertrophy of pancreatic islet.

(Karthikeyan M.,et al.)

Page 25: In- vitro and in-vivo screening of Hypoglycemics.

02/05/202325

Ingle (1941) Forced fed rats, guinea pig and rabbits without

forced feeding are used.

In rats adrenal cortex is stimulated by corticotropin, which secret steroids and

induce steroid diabetes.

Dexamethasone is mostly used.

Corticosteroid

(Karthikeyan M.,et al.)

Page 26: In- vitro and in-vivo screening of Hypoglycemics.

02/05/202326

Adult rats 150-200gm dexamethasone 2-5 mg/kg i.p.

Repeated injection of same dose level is carried out for a period of 20-30 days resulting in Diabetes.

The sample to be screened is administered through a suitable route, blood glucose is measured.

PROCEDURE

(Vogel,G.H.,et al.)

Page 27: In- vitro and in-vivo screening of Hypoglycemics.

02/05/2023

6. VIRUS INDUCED DIABETES

Principle & Rationale Jevunile onset diabetes mellitus may be due

to virus infection and beta-cell specific autoimmunity. (Craighead 1978).

27

6-8 week old mice are injected with D- variant of encephalomyocarditis [EMC] i.p.

Procedure

Page 28: In- vitro and in-vivo screening of Hypoglycemics.

02/05/202328

Pre treatment is given with cyclosporin A.

Drug to be screened is administered orally for a period of 6 weeks.

(Karthikeyan M.,et al.)

Page 29: In- vitro and in-vivo screening of Hypoglycemics.

02/05/202329

7. INSULIN DEFICIENCY DUE TO INSULIN ANTIBODIES

Principle and Rationale

Moloney and Coval(1995); Wright(1968)- A transient diabetic syndrome can be induced by injection of guinea pig anti-insulin

serum.

(Vogel,G.H.,et al.)

Page 30: In- vitro and in-vivo screening of Hypoglycemics.

02/05/202330

Bovine insulin dissolved in acidified water (pH 3.0) at dose of 1mg/ml

Injected to male guinea pig (s.c).

Anti-insulin Sera is collected after two weeks of antigenic challenge.

PREPRATION OF ANTIBODY

Page 31: In- vitro and in-vivo screening of Hypoglycemics.

02/05/202331

Adult albino rats are injected with 0.25-1.0 ml guniea pig anti insulin serum.

Increased of blood glucose level upto 300mg/dl.

The drug sample to be screened is given and glucose level is analysed to determine the

activity.

PROCEDURE

Page 32: In- vitro and in-vivo screening of Hypoglycemics.

02/05/202332

A. SPONTANEOUSLY or GENETICALLY DERIVED DIABETIC ANIMAL

INVIVO MODELS FOR NIDDM

Spontaneously diabetic animals of type 2 diabetes may be obtained from the animals with one or several genetic mutations transmitted from generation to generation (e.g., ob/ob, db/db mice) or by selected from non-diabetic outbred animals by repeated breeding over several generation [e.g., (GK) rat, Tsumara Suzuki Obese Diabetes (TSOD) mouse].

(K. Srinivasan & P. Ramarao)

Page 33: In- vitro and in-vivo screening of Hypoglycemics.

02/05/202333

1. BB rat2. WBN/KOB rat3.GOTO/KAKIZAKI

rat4. ZUKKAR fatty rat5. WDF/ TA-FA rat6. BHE rat

1. KK mice2. KK-Ay mice3. NOD mice4. Obese

hyperglycemic mice5. New Zealand obese

mice6. Transgenic mice

RATS MICE

Other Rat and Mice

Page 34: In- vitro and in-vivo screening of Hypoglycemics.

02/05/202334

BB RAT• Bio Breeding Rat.• Insulin deficiency & insulitis due to

beta-cells destruction.• Nakhooda et al. 1978.

Page 35: In- vitro and in-vivo screening of Hypoglycemics.

02/05/202335

• Classic model of hyperinsulinemic obesity.

• Obesity due autosomal recessive gene which develops at an early age.

• Diabetic phenotype develops due to lipotoxicity to beta cells.

ZUKKER DIABETIC FATTY RAT

Page 36: In- vitro and in-vivo screening of Hypoglycemics.

02/05/202336

KK- Ay MICE • Derived from KK mice.• Carry yellow obese gene• Demonstrate the extra pancreatic action

of glimepirid (Satoh et al. 1994).• Also evaluate ciglitazone (Sohda et al.

1990) .

KK- MICE• Nakamura (1962), reported on a diabetic

strain of the KK mouse.• It is obese animale & showed

polyphagia and polyuria.• Mice at the age of seven months or older

showed glucosuria and blood sugar levels up to 320mg%.

Page 37: In- vitro and in-vivo screening of Hypoglycemics.

02/05/202337

SAND RAT• Small rodent (gerbil).• Indigenous to desert region.• Access to food and water is limited.• Exhibit the genetic predisposition, if fed

with high calorie laboratory diet.

B. DIET / NUTRITION INDUCED DIABETIC ANIMAL

Some of the animal models exist in which diabetes is induced neither by chemicals nor by genetic defect. Sand rat, Tuco-Tuco and Spiny mouse are important models of nutritionally induced obesity and type 2 diabetes.

Page 38: In- vitro and in-vivo screening of Hypoglycemics.

02/05/202338

• Two species of spiny mouse Acomys russates & cahirinus.

• Have congenital hyperplasia of pancreatic islets.

• When laboratory bred, A.cahirinus- weight gain on fat diet with hyperhlycemia.

SPINY MICE

(K. Srinivasan & P. Ramarao)

Page 39: In- vitro and in-vivo screening of Hypoglycemics.

02/05/202339

C. NEONATAL STZ MODEL FOR NIDDM

Neonatal rats : STZ(90 mg /kg) i.p at birth or within the first five days

Rats showing fasting blood glucose level above 140 mg/ dl are considered diabetic.

Drug sample to be screened is administered by a suitable route and blood glucose level is

analyzed (K. Srinivasan & P. Ramarao)

Page 40: In- vitro and in-vivo screening of Hypoglycemics.

02/05/202340

D. TRANSGENIC DIABETIC ANIMAL

Schaefer et al. 1994, described a transgenic mouse model of

chronic hyperglycemia.

Effect of single gene or mutation on diabetes can be

investigated in vivo.

Dissection of complex genetics of type 2 diabetes become

easier.

Highly sophisticated and costly procedure for the production

and maintenance.

Expensive for regular screening experiments.

Page 41: In- vitro and in-vivo screening of Hypoglycemics.

Purpose & Rationale: Was Described extensively by Ross (1927), the perfusion of rat liver from the Portal vein is the most widely used technique.

02/05/202341

EFFECT ON LIVER1. Isolated Rat Liver

INVITRO SCREENING OF HYPOGLYCEMICS

Page 42: In- vitro and in-vivo screening of Hypoglycemics.

02/05/202342

2. Isolated Hepatocytes

Purpose & Rationale: Isolated Hepatocytes can be used

to study the effect of drugs on hepatic gluconeogenisis & other hepatic metabolic reactions such as ketone bodies formation and tricarboxylic acid cycle.

(Vogel,G.H.,et al.)

Page 43: In- vitro and in-vivo screening of Hypoglycemics.

02/05/202343

• Male Wister Rats (200-250gm).• Anasthasized with hexobarbitol 150ml/kg.Animal

• Isolate & washed with 100ml heparinized saline solution.

• Oxygenated air tube connected to portal vein.• Perfusion is done & perfusate is collected.

Isolation & Treatment

• The sample for analysis are withdrawn by catheter & are evaluated for net glucose production.

Evaluation

Procedure

Page 44: In- vitro and in-vivo screening of Hypoglycemics.

02/05/202344

Glucose is evaluated by glucose-oxidase method. And pyruvate, acetoacetate & lactate are evaluated by enzymatic method.

1. The cell suspension is preincubated.2.Substrats are added.

3. Test drug added.

1. Male Wister rat taken.2. Hepatocytes isolated by collagenase method

Procedure

Page 45: In- vitro and in-vivo screening of Hypoglycemics.

02/05/202345

EFFECT ON MUSCLE CELL

Use of Isolated Diaphragm From Mice And Rats

Isolate diaphragm from rats and divide it in equal parts. Incubate it in kreb-henselit buffer with 5mM glucose, insulin or compound to be tested.

After 30 min, hemi diaphragm are blotted on tissue and frozen in liquid nitrogen. Powdered tissue is dissolved in 30% KOH. After freezing samples are centrifuged.

Glycogen Pallets are washed with 70% ethnol & lebelled C14 glycogen determined. Total glycogen is determined after hydrolysis to glucose

The total conc. dependence of glucose uptake & conversion into glycogen by insulin is determined.

Page 46: In- vitro and in-vivo screening of Hypoglycemics.

02/05/2023

• Body Weight.

• HbA1c

• Lipid Profile.

• Serum Insulin Level.

• Histopathology of Pancreas & Liver.

46

Evaluation

Page 47: In- vitro and in-vivo screening of Hypoglycemics.

02/05/202347

References

1. Tripathi,K.D., “Essentials of medical pharmacology”, Jaypee

publications, 2006 (7): 235-236.

2. Vogel,G.H., “Drug Discovery And Evaluation (Pharmacological

Assays)”, Springer, 2002: 999-1044.

3. Gupta,S.K., “Drug Screening Method (Preclinical Evaluation of New

Drugs)”, Jaypee Brothers Medical Publishers Pvt Ltd., 2009: 602-610.

4. K. Srinivasan & P. Ramarao, “Animal models in type 2 diabetes

research: An overview”, Indian J Med Res 125, March 2007: 451-472.

5. S. Lenzen, “The mechanisms of alloxan- and streptozotocin-induced

diabetes”, Diabetologia, Springer-Verlag, 2008 (51): 216–226.

Page 48: In- vitro and in-vivo screening of Hypoglycemics.

02/05/202348

5. Manish Pal Singh and Kamla Pathak, “Animal models for biological

screening of anti-diabetic drugs: An overview”, Pelagia Research

Library, European Journal of Experimental Biology, 2015, 5(5): 37-48.

6. Karthikeyan M, Balasubramanian T and Pawan Kumar, “In-vivo

Animal Models and In-vitro Techniques for Screening Antidiabetic

Activity”, J Develop Drugs 5, 2016 (2): 153-159.

Page 49: In- vitro and in-vivo screening of Hypoglycemics.

02/05/202349